Fidelity Investments
TARS icon

Fidelity Investments’s Tarsus Pharmaceuticals TARS Stock Holding History

Fidelity Investments’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.4M Sell
672,949
-60,385
-8% -$3.86M ﹤0.01% 1581
2026
Q1 		$51.4M Buy
733,334
+86,220
+13% +$6.02M ﹤0.01% 1428
2025
Q4 		$53M Buy
647,114
+625,253
+2,860% +$46.7M ﹤0.01% 1419
2025
Q3 		$1.3M Buy
21,861
+2,011
+10% +$99K ﹤0.01% 2700
2025
Q2 		$804K Buy
19,850
+915
+5% +$41.2K ﹤0.01% 2795
2025
Q1 		$973K Sell
18,935
-14,892
-44% -$736K ﹤0.01% 2687
2024
Q4 		$1.87M Buy
33,827
+28,795
+572% +$1.31M ﹤0.01% 2464
2024
Q3 		$166K Buy
5,032
+3,537
+237% +$99.4K ﹤0.01% 3267
2024
Q2 		$40.6K Sell
1,495
-264
-15% -$8.88K ﹤0.01% 3719
2024
Q1 		$63.9K Buy
1,759
+142
+9% +$4.17K ﹤0.01% 3465
2023
Q4 		$32.7K Buy
1,617
+513
+46% +$8.57K ﹤0.01% 3721
2023
Q3 		$19.6K Buy
1,104
+279
+34% +$4.94K ﹤0.01% 3812
2023
Q2 		$14.9K Sell
825
-301
-27% -$4.79K ﹤0.01% 3991
2023
Q1 		$14.2K Buy
1,126
+978
+661% +$14.3K ﹤0.01% 3991
2022
Q4 		$2.17K Sell
148
-249
-63% -$4.12K ﹤0.01% 4491
2022
Q3 		$7K Buy
397
+269
+210% +$4.27K ﹤0.01% 4214
2022
Q2 		$2K Buy
128
+84
+191% +$1.26K ﹤0.01% 4603
2022
Q1 		$1K Buy
+44
New +$817 ﹤0.01% 4847

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments's TARS Position: Q2 2026 in Review

Fidelity Investments reduced its Tarsus Pharmaceuticals (TARS) stake by 8.2% in Q2 2026, selling an estimated $3.86M and leaving 672,949 shares worth $42.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1581.

Fidelity Investments first reported a position in TARS in Q1 2022 and has held it in 18 quarters since. The position peaked at $53M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Fidelity Investments held 672,949 shares of Tarsus Pharmaceuticals worth $42.4M as of Q2 2026.
  • Fidelity Investments sold 60,385 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.86M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1581 holding.
  • Fidelity Investments first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Fidelity Investments's Tarsus Pharmaceuticals position peaked at $53M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.